Dicinon solution - instructions for use. Etamzilat solution for intravenous and intramuscular administration of SCFC Etamzilat solution instructions for use

Producer: OJSC "Biochemist" Republic of Mordovia

ATC code: B02BX01

Farm group:

Release form: Liquid dosage forms. Injection.

General characteristics. Compound:

Active ingredient: 125 mg of etamsylate.

Excipients: pyro sodium sulphate (sodium disulfite), anhydrous sodium sulphate (sodium sulfite), ethylenediamine disodium salt, tetraacetic acid (Trilon B) (disodium edetate), water for injection.

Etamzilat is a hemostatic drug.

Pharmacological properties:

Pharmacodynamics. The hemostatic effect is based on enhancing the interaction between the endothelium and platelets. It increases platelet adhesion, stabilizes the walls of capillaries, thus reducing their permeability, inhibits the synthesis of prostaglandins, which cause platelet disaggregation, vasodilation and an increase in capillary permeability, which reduces time and reduces blood loss. Increases the rate of formation of the primary thrombus and enhances its retraction, has virtually no effect on the level of fibrinogen and prothrombin time. Restores pathologically altered bleeding time. It does not affect the normal parameters of the hemostasis system. The hemostatic effect with intravenous administration of Etamzilat solution occurs after 5-15 minutes, the maximum effect is after 1-2 hours, the effect lasts for 4-6 hours. When administered intramuscularly, the hemostatic effect occurs in 30-60 minutes

Pharmacokinetics. The drug is well absorbed when administered intramuscularly, weakly binds to plasma proteins and blood cells. Etamzilat is evenly distributed in various organs and tissues (depending on the degree of their blood supply). The half-life of the drug after intravenous administration is 1.9 hours, after intramuscular administration - 2.1 hours. 5 minutes after intravenous administration, 20-30% of the administered drug is excreted by the kidneys, completely - after 4 hours. The effective concentration in the blood is 0.05-0.02 mg / ml. The drug is excreted from the body mainly with urine, in a small amount with bile.

Indications for use:

Capillary bleeding of various etiologies, especially if bleeding is caused by damage to the endothelium: prevention and control of bleeding during and after surgical operations on well-vascularized tissues in otolaryngology, gynecology, obstetrics, urology, dentistry, ophthalmology and plastic surgery; prevention and treatment of capillary bleeding of various etiologies and localizations: metrorrhagia, primary menorrhagia, menorrhagia in women with intrauterine contraceptives, nosebleeds,.

Important! Get to know the treatment

Dosage and administration:

Etamzilat is administered intravenously, intramuscularly, subconjunctivally and retrobulbarno in ophthalmology. Etamzilat can be administered intravenously in a 5% glucose solution or in an isotonic sodium chloride solution.

Adults: for prophylactic purposes during surgical interventions, the drug is administered intravenously or intramuscularly 1 hour before surgery at a dose of 0.25-0.5 g (2-4 ml of a 12.5% ​​solution), if necessary during surgery - at a dose of 0, 25-0.5 g (2-4 ml of 12.5% ​​solution), with the risk of postoperative bleeding - 0.5-0.75 g (4-6 ml of 12.5% ​​solution) during the day.

Children: if necessary, intraoperatively Etamzilat is administered intravenously at the rate of 8-10 mg/kg of body weight. To stop bleeding, Etamzilat is administered intravenously or intramuscularly 0.25-0.5 g (2-4 ml of a 12.5% ​​solution), then every 4-6 hours, 0.25 g (2 ml of a 12.5% ​​solution) in within 5-10 days.

In the treatment of metrot - menorrhagia, Etamzilat is prescribed in a single dose of 0.25 g (2 ml of a 12.5% ​​solution) intravenously or intramuscularly every 6-8 hours for 5-10 days.

In case of diabetic myacroangiopathy, Etamzilat is administered intramuscularly for 10-14 days in a single dose of 0.25-0.5 g three times a day.

In ophthalmology, Etamzilat is administered subconjunctival or retrobulbarno - at a dose of 0.125 g (1 ml of a 12.5% ​​solution).

Application Features:

Caution is required in patients who have ever experienced or.

The drug is ineffective in patients with a reduced number of platelets. In case of hemorrhagic complications associated with an overdose of anticoagulants, it is recommended to use specific antidotes.

The use of etamsylate in patients with impaired parameters of the blood coagulation system is possible, but it should be supplemented by the administration of drugs that eliminate the identified deficiency or defect of the coagulation system factors.

The safety of etamsylate during pregnancy has not been established. Etamzilat should be used during pregnancy only if the potential benefit to the mother outweighs the possible risk to the fetus. Breastfeeding should be discontinued while the mother is being treated with Etamzilat.

Side effects:

Headache, redness of the face, allergic rash, lower extremities, lowering blood pressure.

Interaction with other drugs:

Etamzilat should not be mixed with other drugs. The introduction of the drug at a dose of 10 mg/kg of body weight 1 hour before the introduction of solutions of dextrans with an average molecular weight of 30,000-40,000 Da prevents the antiaggregatory effect of the latter; the introduction of etamsylate after solutions of dextrans does not have a hemostatic effect. It is possible to combine Egamsylate with aminocaproic acid and menadione sodium bisulfite.

Contraindications:

Acute, hemoblastosis in children, hypersensitivity to any ingredient of the drug; thrombosis; thromboembolism.

With caution - with bleeding on the background of an overdose of anticoagulants, pregnancy.

Storage conditions:

Shelf life 4 years. After the expiration date, do not use In a dry, dark place at a temperature not exceeding 25 ° C. In a place inaccessible to children.

Leave conditions:

On prescription

Package:

Solution for intravenous and intramuscular administration 125 mg/ml. 2 ml in ampoules. 5 ampoules are placed in blisters. 1, 2 blister packs are placed in a pack of cardboard. 10 ampoules in a carton pack. The pack is pasted over with a label - a parcel made of label paper or coated paper. Each pack contains instructions for use, an ampoule knife or an ampoule ceramic scarifier. When using ampoules with notches, dots or rings, the ampoule knife is not inserted.

Photo of the drug

Latin name: Etamsylate

ATX Code: B02BX01

Active substance: Etamzilat (Etamsylate)

Producer: Lugansk HFZ, Ukraine; pilot plant GNTsLS DP Ukrmedprom, Ukraine; Pharma Firm SOTEKS, Russia; BIOCHEMIK, Russia; BIOSINTEZ, Russia

The description applies to: 18.10.17

Etamzilat is a drug that increases the formation of mucopolysaccharides in the capillary walls, and also increases the stability of microvessels.

Release form and composition

Produced in the form of a clear, colorless solution for injection and biconvex, round white tablets. The solution is sold in glass ampoules of 2 ml in cardboard packaging. Tablets are sold in blisters placed in cardboard boxes.

Indications for use

• stopping and preventing capillary bleeding in diabetic angiopathy;
• ophthalmic operations (keratoplasty, cataract removal, antiglaucoma surgery);
• urological operations (for example, prostatectomy);
• surgical interventions in the otolaryngological field (ear microsurgery, tonsillectomy, etc.);
• dental operations (tooth extraction, removal of cysts, granulomas);
• gynecological operations;
• surgical interventions on abundantly vascularized tissues and organs;
• emergency situations with intestinal and pulmonary bleeding;
• hemorrhagic diathesis.

Contraindications

• increased individual sensitivity to the components of the drug;
• bleeding that is provoked by the action of anticoagulants;
• embolism and thrombosis in history.

Instructions for use Etamzilat (method and dosage)

It is intended for oral, subconjunctival, intravenous, intramuscular and retrobulbar use.

• In / in, in / m 1 hour before surgery, for prevention - 0.25–0.5 g (2–4 ml of a 12.5% ​​solution). With the risk of postoperative bleeding - 0.5–0.75 g (4–6 ml) per day.
• If necessary, during the operation, 0.25–0.5 g (2–4 ml) is administered intravenously. For medicinal purposes - 0.25–0.5 g (2–4 ml) at once, and then 0.25 g every 4–6 hours.
• With metro and menorrhagia, 0.25 g is prescribed every 6 hours for 5–10 days, then 0.25 g 2 times a day during hemorrhage.
• With hemorrhagic diathesis and diabetic microangiopathies, 0.25-0.5 g is usually prescribed 1-2 times a day.
• The dosage for subconjunctival and retrobulbar use is one milliliter.

Side effects

The use of Etamzilat can cause the following side effects:

• From the side of the cardiovascular system: arterial hypotension, thromboembolism.
• From the nervous system: dizziness, headache, hot flashes, paresthesia.
• From the digestive system: epigastric pain, nausea, vomiting, diarrhea.
• From the immune system: fever, allergic reactions (skin rashes, itching, urticaria, anaphylactic shock, angioedema).
• Other: acute porphyria, back pain, bronchospasm.

Overdose

No information available.

Analogues

Analogues for the ATX code: Dicinon, Etamzilat-Ferein, Etamzilat-Eskom.

Do not make the decision to change the drug yourself, consult your doctor.

pharmachologic effect

• Etamzilat is an effective hemostatic agent that normalizes microcirculation and improves capillary permeability in pathological processes. The hemostatic effect is due to stimulation of the formation of thromboplastin. The use helps to enhance the formation of the third factor of blood coagulation and improve platelet adhesion.
• It does not have hypercoagulable properties, does not affect PTI and does not contribute to thrombosis.
• Begins to show its hemostatic properties 5-10 minutes after oral use. The maximum therapeutic effect is observed one hour after taking the medicine. The duration of pharmacological action ranges from four to six hours.
• The maximum concentration of the active substance in the blood plasma is reached 10 minutes after the injection.
• The drug is excreted from the body unchanged in the urine for 24 hours. The half-life is two hours.

special instructions

Incompatible with other drugs.

During pregnancy and breastfeeding

During pregnancy, it is prescribed only under strict indications.

Instructions for injections Etamzilat is designed to familiarize the patient with information about the drug. It also describes in detail the methods of using the drug and gives warnings about side effects and contraindications to the appointment.

Pharmacology

In terms of pharmacology, the drug has a hemostatic and angioprotective effect.

Etamzilat stimulates the formation of platelets with their subsequent release from the bone marrow. Also, due to its effect, the formation of tissue thromboplastin is activated in those places where small vessels are damaged, the degree of bleeding decreases.

With the use of Etamzilat, the bleeding time, which has received a pathological change, is restored. The drug does not cause hypercoagulation and vasoconstriction. The stability of capillaries increases with a decrease in their fragility and their permeability is normalized.

Pharmacokinetics

The drug is highly absorbed with any method of administration. It has a uniform distribution in tissues and organs. It binds poorly to plasma proteins.

Excretion from the body occurs quite quickly, almost invariably, mainly through the kidneys and slightly with the contents of the intestine. It takes at least four hours for the drug to be completely evacuated from the body.

With intravenous administration of Etamzilat, hemostasis is activated within 15 minutes, reaching its maximum after two hours, the level of which lasts for about six hours. Then it gradually weakens and disappears by the end of the day. Using intramuscular administration of the drug, the development of a therapeutic effect will have to wait longer.

Etamzilat indications for use

A drug is prescribed to prevent the development of bleeding and stop them both in life-threatening parenchymal bleeding in case of damage to internal organs, and in capillary ones.

As well as the use of the drug is shown:

• with traumatic bleeding in the field of surgery and during operations;
• in the field of dentistry (tooth extraction, cysts, granulomas);
• In the urological area (with prostatectomy);
• in the field of ophthalmology (during keratoplasty or other operations, cataract removal);
• in the field of otoringology (with tonsillectomy, microsurgical operations in the ear area);
• with internal bleeding (intestinal, pulmonary, renal, with fibromas);
• with secondary manifestations of bleeding in diseases such as thrombocytopenia and thrombocytopathy;
• in a state of hypocoagulation;
• with hematuria;
• with intracranial hemorrhages;
• with bleeding from the nose associated with arterial hypertension;
• with an overdose of anticoagulants;
• with hemorrhagic diathesis and vasculitis;
• with hemorrhagic syndrome associated with vascular disease;
• with diabetic microangiopathy.

Contraindications

The list of contraindications of the drug is not very diverse, however, it warns of its undesirable appointment if the patient has:

• hypersensitivity;
• hemoblastosis in childhood;
• thrombosis;
• acute porphyria;
• thromboembolism.

Also, the drug should be limited when the patient suffers from hemorrhage during treatment with anticoagulants.

Etamzilat instructions for use

The dosage of the drug is calculated by the doctor with an individual approach to the patient and his indications for the use of Etamzilat intravenously.

The optimal dose per day, both intravenously and intramuscularly, should be considered:

• for an adult patient, from 10 to 20 milligrams / kilogram divided into 3 injections;
• a pediatric patient from 10 to 15 milligrams / kg. divided into three or four introductions.

An injectable solution can be administered for topical application by applying a sterile drug-soaked swab to the damaged area. It can also be used as eye drops.

Etamzilat injections during pregnancy

During pregnancy, Etamzilat injections are allowed with an urgent need for therapy, while it should be borne in mind that the safety of the drug for patients in this category has not been confirmed. Breastfeeding during treatment is not worth it.

Side effects

Complications to taking Etamzilat in the form of side effects may develop the following:

• in the form of dizziness, allergies, headaches, heaviness in the epigastric region, flushing of the skin of the face, heartburn, paresthesia of the extremities (lower), falling blood pressure.

Overdose

Cases of overdose were not recorded.

Drug Interactions

Do not mix Etamzilat in syringes with other medicines.

If you enter the drug before taking dextrans (blood plasma substitutes), this will prevent their antiaggregation. When the introduction of Etamzilat will be made after this solution, this will reduce the effect of hemostatics.

Etamzilat can be combined with menadione sodium bisulfite or with the required amount of aminocaproic acid.

Additional instructions

Patients with a history of thrombosis or thromboembolism may take etamzilat, but with caution.

With complications of a hemorrhagic nature, which can be caused by an overdose of anticoagulant drugs, you will need to use a specific antidote.

For those who have impaired blood clotting, treatment should be supplemented with the necessary medicines to eliminate this defect.

Etamzilat analogues

The analogues of the drug Etamzilat are the drug Dicinon, as well as several varieties of Etamzilat from different manufacturers (Ferein, Eskom and others).

Etamzilat price

The cost of the drug is low, but it should be clarified when purchasing it.

Etamzilat

International non-proprietary name

Etamzilat

Dosage form

Solution for injection 12.5%, 2 ml

Compound

One ampoule contains

active substance- etamsylate - 250.0 mg,

Excipients: sodium metabisulfite, sodium sulfite anhydrous, water for injection.

Description

Clear, colorless or slightly colored liquid.

Pharmacotherapeutic group

Hemostatics. Vitamin K and other hemostatics. Other systemic hemostatics. Etamzilat.

ATX code B02BX01

Pharmacological properties

Pharmacokinetics

After intravenous administration of 500 mg of etamsylate, the maximum plasma concentration is reached after 10 minutes; the plasma half-life is approximately 1.9 hours. About 85% of the dose taken is excreted in the urine during the first 24 hours.

The degree of binding to plasma proteins is approximately 95%. The plasma half-life is approximately 3.7 hours. About 72% of the dose taken is excreted unchanged during the first 24 hours in the urine. Etamsylat crosses the placental barrier. Maternal and cord blood contain similar concentrations of etamsylate. It is not known whether etamsylate passes into breast milk.

Pharmacokinetics in patients with hepatic and renal insufficiency has not been studied.

Pharmacodynamics

Etamzilat is a synthetic hemostatic and angioprotective drug used as a primary hemostatic agent, which is due to increased interaction between the endothelium and platelets, which promotes adhesion and aggregation of platelets, and ultimately leads to a stop or decrease in bleeding. The hemostatic effect of etamsylate develops when administered intravenously after 5-15 minutes, the maximum effect occurs after 1-2 hours, the effect lasts 4-6 hours or more. With intramuscular injection, the effect occurs somewhat more slowly. When taken orally, the maximum effect is noted after 3 hours. Etamzilat stimulates the formation of platelets and their release from the bone marrow, accelerates the formation of tissue thromboplastin, increases the rate of formation of the primary thrombus at the site of injury and enhances its retraction. Etamzilat enhances the formation of high molecular weight mucopolysaccharides in the capillary wall, increases the resistance of capillaries, normalizes their permeability in pathological processes and improves microcirculation. Against the background of treatment with Etamzilat, pathologically altered hemostasis parameters are restored. Etamzilat does not have a vasoconstrictive effect, does not affect fibrinolysis and does not change plasma coagulation factors.

Indications for use

Prevention and stopping of capillary and parenchymal bleeding of various etiology and localization in otorhinolaryngology, microsurgery, ophthalmology, dentistry, urology, surgery and gynecology.

Hematuria

Intracranial hemorrhage (including in newborns and premature babies)

Nosebleeds due to arterial hypertension

Bleeding due to medication

Hemorrhagic diathesis (including Werlhof disease, Willebrand-Jurgens disease, thrombocytopathy)

Dosage and administration

adults

Before surgery: 1-2 ampoules (250 - 500 mg) intravenously or intramuscularly 1 hour before surgery.

During the operation(if necessary): 1-2 ampoules (250 - 500 mg) intravenously.

After operation(prophylactically): if there is a risk of bleeding, after surgery, 1-2 ampoules (250-500 mg) should be administered prophylactically intravenously or intramuscularly every 4-6 hours.

Emergency cases, according to the severity of the case: 1-2 ampoules intravenously or intramuscularly every 4-6 hours for as long as there is a risk of bleeding.

Local treatment: moisten the swab with the contents of the ampoule and apply to the site of bleeding, or the tooth socket after tooth extraction. If necessary, the application of a tampon moistened with the contents of the ampoule can be repeated, or combined with oral or parenteral administration of the drug.

Children: the daily dose is 10-15 mg/kg of body weight, divided into 3-4 doses.

Neonatology: Etamsylate should be administered intramuscularly or intravenously at 10 mg/kg body weight (0.1 ml = 12.5 mg), within 2 hours after birth, and then every 6 hours for 4 days.

Special Populations:

The use of the drug in the form of a solution for injection in patients with hepatic or renal insufficiency should be carried out under the strict supervision of a physician.

Side effects

Adverse reactions are listed by MedDRA classification by organ class and frequency as follows:

Very common (≥ 1/10)

Often (≥ 1/100,<1/10)

Uncommon (≥ 1/1000,<1/100)

Rare (≥ 1/10000 to<1/1000)

Rarely (<1/10000), не известно (из имеющихся данных не могут быть оценены)

From the digestive system

Often

Nausea, abdominal pain, abdominal discomfort, diarrhea

From the skin and subcutaneous tissue

Often

Skin rash

From the side of the nervous system

Often

Headache, vascular disorders

Rarely

Thromboembolism, hypotension

From the blood and lymphatic system

Rarely

- agranulocytosis, neutropenia, thrombocytopenia

From the side of the musculoskeletal system

Rarely

Arthralgia

From the side of the immune system

Rarely

Allergic reactions (anaphylactic shock, life-threatening asthma attacks)

Often

Asthenia

Rarely

Fever

These side effects are usually reversible and disappear after treatment.

In the event of adverse skin reactions or fever, discontinue treatment and inform your doctor as these may be the first signs of hypersensitivity.

Contraindications

Hypersensitivity to any component of the drug

Acute porphyria

Bronchial asthma

Hemoblastosis in children (lymphoblastic and myeloid leukemia, osteosarcoma)

Thrombosis, thromboembolism

Drug Interactions

Introduction at a dose of 10 mg/kg of body weight 1 hour before the administration of dextrans (average molecular weight 30-40 thousand Da) prevents their antiaggregant effect. The introduction of Etamzilat after the introduction of dextrans does not have a hemostatic effect.

Perhaps a combination with aminocaproic acid and menadione sodium bisulfite.

Pharmaceutically incompatible (in one syringe) with other drugs.

If simultaneous administration with dextran is necessary, the etamsylate solution should be administered first.

According to studies, when administered intravenously, Etamzilat can affect the blood levels of creatinine, lactate, triglycerides, uric acid and cholesterol, determined by the enzymatic method, for up to 12 hours. During treatment with Etamzilat, it is recommended that samples (eg, blood) be taken before the first administration of the drug in order to minimize the impact on laboratory results.

special instructions

Caution is required (despite the absence of thrombus induction) when prescribing Etamzilat to patients with a history of thrombosis or thromboembolism.

In hemorrhagic complications associated with an overdose of anticoagulants, it is recommended to use specific antidotes. The use of Etamzilat in patients with impaired parameters of the blood coagulation system is possible, but it should be supplemented by the administration of drugs that eliminate the identified deficiency or defect of the coagulation system factors.

Before starting treatment, it must be borne in mind that the drug is ineffective in patients with thrombocytopenia.

Since parenteral administration of the drug Etamsylat can cause a decrease in blood pressure, careful monitoring of patients suffering from changes in blood pressure or hypotension should be carried out.

Etamzilat contains sulfites, which is why it is also necessary to be careful when administering it to patients with allergies.

In the event of an allergic reaction, treatment with the drug should be discontinued immediately.

Pregnancy and lactation.

Application during pregnancy is possible only in cases where the potential benefit of therapy for the mother outweighs the possible risk to the fetus. If necessary, the appointment of the drug during lactation should decide on the termination of breastfeeding.

Features of the influence of the drug on the ability to drive a vehicle or potentially dangerous mechanisms

There is no data on the effect of the drug on the ability to manage transport and other mechanisms that require concentration.

Overdose

Cases of overdose have not been identified. In case of overdose, treatment is symptomatic.

Release form and packaging

2.0 ml of the drug is poured into neutral glass ampoules or sterile syringe-filled ampoules, or imported.

Each ampoule is labeled with label paper or writing paper, or the text is applied directly to the ampoule with gravure printing ink for glass products.

5 ampoules are packed in a blister pack of film

PVC and aluminum foil

2 or 10 contour packs, together with the approved instructions for medical use in the state and Russian languages, are placed in a cardboard pack. An ampoule scarifier is put into each pack. When packing ampoules with notches, rings and dots, scarifiers are not included.

It is allowed to place blister packs (without investing in a pack of cardboard) into cardboard boxes. According to the number of packages, each box contains instructions for medical use in the state and Russian languages.

Storage conditions

Store in a dry, dark place at a temperature not exceeding 25°C.

Keep out of the reach of children!

Shelf life

Do not use after the expiration date.

Terms of dispensing from pharmacies

On prescription

Manufacturer

JSC "Khimfarm", Kazakhstan,

Shymkent, st. Rashidova, 81

Registration certificate holder

JSC Chimpharm, Kazakhstan

Address of the organization accepting claims from consumers on the quality of products (goods) on the territory of the Republic of Kazakhstan

JSC Chimpharm, Kazakhstan

Shymkent st. Rashidova, 81

Fax number +7 7252 (561342)

Name, address of the organization on the territory of the Republic of Kazakhstan responsible for post-registration surveillance of the safety of the medicinal product

JSC "Khimfarm", Republic of Kazakhstan, Shymkent, st. Rashidova, 81,

Phone number +7 7252 (561342)

Fax number +7 7252 (561342)

E-mail address [email protected]

1 ml of solution contains

active substance- etamsylate 125 mg,

Excipients: sodium metabisulfite, sodium sulfite anhydrous, disodium edetate (Trilon B), water for injection.

Description

Clear, colorless or slightly creamy liquid

Pharmacotherapeutic group

Hemostatics. Vitamin K and other hemostatics. Other systemic hemostatics. Etamzilat.

ATX code B02B X01.

Pharmacological properties

Pharmacokinetics

After intravenous (in / in) or intramuscular (in / m) administration of Etamzilat at a dose of 500 mg, its concentration in blood plasma after 1 hour is 30 μg / ml. The hemostatic effect with the on / in the introduction of Etamzilat occurs after 5-15 minutes, the maximum effect - after 1-2 hours, the effect lasts 4-6 hours. With the / m administration, the hemostatic effect occurs after 30-60 minutes. The elimination half-life after intravenous administration is 1.9 hours, after intramuscular injection - 2.1 hours. 95% of the administered drug binds to plasma proteins. Etamzilat is not metabolized and is excreted unchanged mainly in the urine (> 80%), partially excreted in the bile and feces.

Pharmacodynamics

The drug has a hemostatic effect. The hemostatic effect is due to increased interaction between the endothelium and platelets, which promotes adhesion and aggregation of platelets, and, ultimately, leads to a stop or decrease in bleeding. Etamzilat stimulates the formation of platelets and their release from the bone marrow, accelerates the formation of tissue thromboplastin, increases the rate of formation of the primary thrombus at the site of injury and enhances its retraction. Etamzilat enhances the formation of high molecular weight mucopolysaccharides in the capillary wall, increases the resistance of capillaries, normalizes their permeability in pathological processes and improves microcirculation. Against the background of treatment with Etamzilat, pathologically altered hemostasis parameters are restored.

Indications for use

Prevention and control of bleeding during surgical interventions:

In otorhinolaryngology (tonsillectomy, microsurgical operations on the ear)

Ophthalmology (keratoplasty, cataract removal, antiglaucoma

operations)

In dentistry (removal of cysts, granulomas, extraction of teeth)

In urology (prostatectomy)

In surgery (operations on well-vascularized organs and tissues)

In gynecology

In traumatology

In emergency cases with pulmonary, intestinal bleeding

Metro- and menorrhagia with fibromas

Diabetic angiopathy

Hemorrhagic diathesis (including in emergency cases)

Dosage and administration

Etamzilat is used intravenously, intramuscularly, subconjunctivally or retrobulbarno. As a preventive measure for adults, the drug is administered intravenously or intramuscularly 1 hour before surgery, 0.25-0.5 g (2-4 ml of a 12.5% ​​solution). If necessary, during the operation, it is administered intravenously at a dose of 2-4 ml of a 12.5% ​​solution. If there is a risk of postoperative bleeding, 4-6 ml of a 12.5% ​​solution per day is administered for prophylactic purposes. For medicinal purposes, in emergency cases, adults are administered Etamzilat intravenously or intramuscularly (2-4 ml of a 12.5% ​​solution), and then 2 ml every 4-6 hours. In the treatment of metrorrhagia and menorrhagia, Etamzilat is prescribed 0.25 g (2 ml of a 12.5% ​​solution) parenterally every 6-8 hours for 5-10 days, and then - 0.25 g (2 ml 12.5 % solution) parenterally 2 times a day during bleeding and 2 subsequent cycles.

In diabetic angiopathy, adults are prescribed Etamzilat intramuscularly (10-14 days), 2 ml 2 times a day.

Subconjunctival or retrobulbar (keratoplasty, cataract removal, glaucoma surgery, etc.) 1 ml of a 12.5% ​​solution is injected.

For children, including newborns, with severe hemorrhages, the drug is administered once intravenously or intramuscularly, 0.5-2 ml, taking into account body weight (10-15 mg / kg).

You can apply the solution for injection topically: a sterile swab soaked in the drug is applied to the wound.

The maximum single dose for adults is 4 mg (0.5 g), daily 14 mg (1.75 g).

Side effects

Headache, dizziness

Decreased blood pressure, feeling of heaviness in the heart

Hyperemia of the face, paresthesia of the lower extremities

allergic rash

Allergic reactions (skin rashes, anaphylactic shock, life-threatening asthma attacks)

Backache

Nausea, bitterness in the mouth, epigastric pain, diarrhea

Contraindications

Hypersensitivity to the drug

Hemorrhages caused by anticoagulants

Thrombosis or embolism in history

lactation period

Bronchial asthma

Hemoblastosis in children (lymphatic and myeloid leukemia, osteosarcoma)

Acute porphyria

Drug Interactions

Etamzilat solution should not be mixed in the same syringe with other drugs. When used together with rheopolyglucin, the effects of both drugs are completely inhibited. If necessary, intravenous drip of the drug, Etamzilat is added to a glucose solution or physiological sodium chloride solution.

special instructions

Caution is required in patients with a history of thrombosis or thromboembolism. With hemorrhagic complications associated with an overdose of anticoagulants, it is necessary to use specific antidotes. Etamzilat is prescribed only as an adjuvant and, mainly, in case of violations of the platelet-vascular component of hemostasis. The drug is not effective in patients with thrombocytopenia.

Be wary appoint patients with cardiac arrhythmias and angina pectoris.

Etamzilat contains sulfites, which is why it is also necessary to be careful when administering it to patients with bronchial asthma and allergies.

In the event of an allergic reaction, treatment should be discontinued immediately.

Pregnancy

The use of etamzilat during pregnancy is possible only if the expected effect of therapy outweighs the potential risk to the fetus.

Features of the influence of the drug on the ability to drive a vehicle or potentially dangerous mechanisms